This Next Billion-Dollar Startup Makes Longevity Drugs For Dogs (And What It Could Mean For Humans)

Uncover the future of aging with Loyal, the biotech company leading a quiet revolution. Led by founder Celine Halioua, Loyal is unravelling the fundamental mechanisms of pathological aging in our beloved companions. Their mission? To extend the healthy lives of dogs and, in doing so, reveal unprecedented insights into human longevity.

Loyal joins the 2025 Forbes Next Billion-Dollar Startups list and involves the largest animal clinical trial ever conducted, enrolling 1,300 dogs across 70 veterinary clinics nationwide. The goal: to give dogs "one healthier year" and yield a "gold mine of data" that will fundamentally advance the understanding of aging in both canines and humans.

Could the secret to a longer, healthier human lifespan be found in the journey of our canine companions? Loyal's unofficial slogan hints at the profound answer: "save the dogs, save the world".

Read the full story on Forbes

Subscribe to FORBES

Fuel your success with Forbes. Gain unlimited access to premium journalism, including breaking news, groundbreaking in-depth reported stories, daily digests and more. Plus, members get a front-row seat at members-only events with leading thinkers and doers, access to premium video that can help you get ahead, an ad-light experience, early access to select products including NFT drops and more:

Stay Connected

Forbes newsletters

Forbes on Facebook

Forbes Video on Twitter

Forbes Video on Instagram

More From Forbes

Forbes covers the intersection of entrepreneurship, wealth, technology, business and lifestyle with a focus on people and success.